How Long Do Sulphur Burps Last with Mounjaro?

Sulphur burps—belching with a distinctive rotten egg odour—are a recognised gastrointestinal side effect of Mounjaro (tirzepatide), a dual GLP-1 and GIP receptor agonist used to treat type 2 diabetes mellitus in the UK. These unpleasant burps typically occur during the initial weeks of treatment or following dose increases, often resolving within a few weeks as the body adapts. However, duration varies considerably between individuals, with some experiencing intermittent symptoms for longer periods. Understanding why sulphur burps occur, how long they typically last, and effective management strategies can help patients continue benefiting from Mounjaro's significant glycaemic and weight management effects whilst minimising discomfort.

Understanding Sulphur Burps with Mounjaro

Mounjaro (tirzepatide) is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. It is administered as a once-weekly subcutaneous injection that can be given at any time of day, with or without food. Whilst this medication offers significant benefits in glycaemic control and weight management, patients commonly report gastrointestinal side effects during treatment.

Eructation (belching) is a recognised gastrointestinal adverse effect of Mounjaro documented in clinical trials and the product's Summary of Product Characteristics (SmPC). Some patients describe these as sulphur burps – belching with a distinctive hydrogen sulphide odour reminiscent of rotten eggs. This occurs when gas containing hydrogen sulphide accumulates in the digestive system and is expelled through the mouth. The experience can be both embarrassing and uncomfortable, sometimes accompanied by other gastrointestinal symptoms such as nausea, bloating, or altered bowel habits.

Gastrointestinal adverse effects, including eructation, are well-documented with GLP-1 receptor agonist therapies in the MHRA/EMC SmPC for Mounjaro. Understanding that these are recognised side effects can provide reassurance to patients who may otherwise feel concerned about their symptoms.

It is important to note that whilst sulphur burps are unpleasant, they are generally considered a manageable side effect rather than a serious adverse reaction. However, their impact on quality of life should not be underestimated, and patients experiencing persistent or severe symptoms should discuss management strategies with their healthcare provider.

Typical Duration of Sulphur Burps on Mounjaro

The duration of sulphur burps experienced by patients taking Mounjaro varies considerably between individuals. According to clinical trial data and post-marketing experience, gastrointestinal side effects including belching typically occur during the initial weeks of treatment or following dose escalation. For many patients, these symptoms often improve within weeks, especially during the dose titration phase.

Gastrointestinal adverse effects, including eructation, represent a transient side effect for many patients. The SURPASS clinical trial programme for tirzepatide demonstrated that gastrointestinal adverse effects were most frequent during dose escalation periods and generally decreased in frequency and severity with continued treatment.

However, a subset of patients may experience intermittent sulphur burps that persist beyond the initial adaptation period, particularly if dietary triggers are present or during subsequent dose increases. The MHRA's product information for Mounjaro acknowledges that gastrointestinal side effects can occur throughout treatment, though their frequency and severity typically decrease over time.

Individual variation is substantial, influenced by factors such as baseline gastrointestinal function, dietary habits, dose level, and concurrent medications. The SmPC for Mounjaro notes that slower dose titration or temporary pauses in dose escalation may help mitigate gastrointestinal adverse effects. If sulphur burps persist beyond 4–6 weeks at a stable dose, or if they worsen rather than improve, this warrants medical review to exclude other potential causes and consider management adjustments.

Why Mounjaro Causes Sulphur Burps

Understanding the mechanism of action of Mounjaro helps explain why belching, including sulphur burps, may occur. As documented in the SmPC, tirzepatide works by activating both GLP-1 and GIP receptors, which leads to multiple physiological effects including enhanced insulin secretion, suppressed glucagon release, and importantly, delayed gastric emptying. This slowing of stomach emptying is beneficial for glycaemic control and satiety but can contribute to gastrointestinal symptoms.

When gastric emptying is delayed, food remains in the stomach and upper digestive tract for longer periods. This extended transit time may create conditions where bacterial fermentation of food particles could occur. Proteins from eggs, meat, dairy products, and certain vegetables contain sulphur-containing amino acids such as methionine and cysteine. The fermentation of these compounds can theoretically produce hydrogen sulphide gas, which would be responsible for the characteristic rotten egg odour in belching.

Additionally, Mounjaro's effects on gut motility may influence the production and clearance of intestinal gases. The medication is associated with dyspepsia and gastro-oesophageal reflux, which can contribute to increased belching.

Dietary factors play a significant role in symptom severity. High-protein diets, particularly those rich in sulphur-containing foods, may exacerbate sulphur burp production. Furthermore, the nausea that some patients experience with Mounjaro may lead to dietary changes or irregular eating patterns, which can further disrupt normal digestive processes and contribute to gas accumulation. While there is no direct evidence that Mounjaro specifically increases sulphur production, its effects on gastrointestinal physiology may create conditions that contribute to belching with a sulphurous odour in some patients.

Managing and Reducing Sulphur Burps

Several strategies can help patients manage and reduce sulphur burps whilst continuing Mounjaro therapy. Dietary modification represents the first-line approach and often provides significant relief.

Dietary adjustments include:

• Reducing sulphur-rich foods such as eggs, red meat, poultry, dairy products, cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), garlic, and onions, particularly during the initial treatment period

• Eating smaller, more frequent meals rather than large portions, which can overwhelm the already-slowed digestive system

• Avoiding carbonated beverages and foods that promote gas production, including beans, lentils, and certain artificial sweeteners

• Staying well-hydrated with water throughout the day to support digestive function

• Limiting fatty and fried foods, which further delay gastric emptying

Lifestyle modifications can also prove beneficial:

• Taking Mounjaro on the same day each week as directed (it can be administered at any time of day, with or without food, per the SmPC)

• Eating slowly and chewing food thoroughly to reduce air swallowing (aerophagia)

• Avoiding lying down immediately after meals; remaining upright for at least 2–3 hours aids digestion

• Engaging in gentle physical activity, such as walking after meals, to promote gut motility

Over-the-counter remedies may provide symptomatic relief, though patients should consult their pharmacist or GP before use:

• Simeticone-containing products may help disperse gas bubbles

• Ginger may soothe the digestive system

• Peppermint tea may help, though it can worsen reflux in some people

• Alginate/antacid preparations if reflux symptoms are present

• Probiotics might help restore gut bacterial balance, though evidence for this specific indication is limited

Patients should maintain their prescribed Mounjaro dosing schedule unless advised otherwise by their healthcare provider. Discussing slower dose titration with your prescriber may help if gastrointestinal side effects are troublesome. Abruptly stopping or reducing the dose without medical guidance can compromise diabetes management.

When to Seek Medical Advice

Whilst sulphur burps are generally a benign side effect of Mounjaro, certain circumstances warrant prompt medical attention. Patients should contact their GP or diabetes specialist nurse if they experience:

Red flag symptoms requiring urgent assessment:

• Severe, persistent abdominal pain, particularly if localised or accompanied by fever, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 receptor agonists). If pancreatitis is suspected, stop taking Mounjaro immediately and seek urgent medical attention

• Severe pain in the upper right abdomen, possibly with fever or yellowing of the skin/eyes (jaundice), which could indicate gallbladder disease

• Persistent vomiting lasting more than 24 hours or inability to keep down fluids, risking dehydration

• Blood in vomit or stools, which may indicate gastrointestinal bleeding

• Signs of dehydration including dark urine, dizziness, confusion, or reduced urine output

• Severe diarrhoea with more than six loose stools in 24 hours

• Unexplained weight loss beyond expected therapeutic effects

For these urgent symptoms, call NHS 111 for immediate advice or 999/attend A&E for severe symptoms such as suspected pancreatitis, gastrointestinal bleeding, or severe dehydration.

Non-urgent but important reasons to schedule a routine appointment:

• Sulphur burps persisting beyond 4–6 weeks at a stable dose without improvement

• Symptoms significantly impacting quality of life, work, or social functioning

• Worsening symptoms despite dietary and lifestyle modifications

• New or changing gastrointestinal symptoms that differ from initial side effects

• Concerns about medication adherence due to side effects

Your healthcare provider can assess whether symptoms represent expected medication effects or require investigation for alternative causes such as Helicobacter pylori infection, small intestinal bacterial overgrowth (SIBO), or other gastrointestinal conditions. They may consider dose adjustment, additional symptomatic treatment, or in rare cases, switching to an alternative diabetes medication if side effects prove intolerable despite management strategies. NICE guidance emphasises the importance of individualised treatment approaches that balance glycaemic benefits against tolerability.

Patients are encouraged to report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Long-Term Outlook and Adaptation

The long-term prognosis for patients experiencing sulphur burps with Mounjaro is generally favourable, with most individuals achieving significant symptom improvement or complete resolution as treatment continues. Clinical experience demonstrates that the gastrointestinal system typically adapts to tirzepatide's effects over time, with the majority of patients able to continue therapy successfully.

Adaptation timeline: Data from the SURPASS clinical trial programme for tirzepatide indicates that gastrointestinal adverse effects, including eructation and related symptoms, show a temporal pattern. The highest incidence occurs during the initial weeks of treatment and with each dose escalation. With continued treatment at a stable dose, many patients report substantial reduction in gastrointestinal symptoms. This adaptation reflects physiological adjustment to altered gastric emptying and gut motility.

Sustained treatment benefits: For patients with type 2 diabetes, continuing Mounjaro despite initial side effects often proves worthwhile. According to NICE guidance and the SURPASS clinical trials, the medication provides significant improvements in HbA1c levels and body weight. Once the gastrointestinal system adapts, many patients find they can gradually reintroduce previously restricted foods without symptom recurrence, though individual tolerance varies.

Ongoing management: Patients who experience recurrent sulphur burps during dose escalations can apply the same dietary and lifestyle strategies that proved effective initially. Some individuals find that maintaining certain dietary modifications long-term, such as moderating sulphur-rich foods, helps prevent symptom recurrence whilst allowing continued dose optimisation.

It is worth noting that alternative incretin-based therapies exist if Mounjaro proves persistently intolerable, though all medications in this class carry similar gastrointestinal side effect profiles. Your diabetes care team can discuss the full range of treatment options if needed, ensuring that diabetes management remains effective whilst minimising adverse effects on quality of life.

Frequently Asked Questions